Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Reference pricing system and competition: case study from Portugal.Croatian medical journal · 2009
   Article
2. Does knowledge of medication prices predict physicians' support for cost effective prescribing policies.The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique · 2008
   Article
3. Reference drug pricing.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2002
   Article
4. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.PharmacoEconomics · 2002
   Review

Corrections and comments

• Commented on by
  Reference drug pricing.2002
• Comment on
  Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.2002

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as